Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adherence to Otezla in Mild Psoriasis
NCT05601492Phase 1Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in psoriasis (3 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Medication Adherence Outlier at Month 6. Planned start Jun 2025; status: withdrawn.
02
Drugs
apremilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05601492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601492.